Patents by Inventor William H. Brondyk

William H. Brondyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF)
    Publication number: 20230322873
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Application
    Filed: December 14, 2022
    Publication date: October 12, 2023
    Inventors: Catherine R. O’RIORDAN, William H. BRONDYK
  • Multispecific binding molecules having specificity to dystroglycan and laminin-2
    Patent number: 11254737
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: February 22, 2022
    Assignee: SANOFI
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2
    Publication number: 20200317761
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Application
    Filed: March 13, 2020
    Publication date: October 8, 2020
    Inventors: Christian BEIL, William H. BRONDYK, Yangde CHEN, Seng H. CHENG, Timothy D. CONNORS, Catherine DEVAUD, Dietmar HOFFMANN, Christian LANGE, Maureen MAGNAY, Tristan MAGNAY, Catherine PRADES, Ercole RAO, Leila SEVIGNY, Ronnie WEI, Hongmei ZHAO, Yunxiang ZHU
  • Multispecific binding molecules having specificity to dystroglycan and laminin-2
    Patent number: 10626169
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: April 21, 2020
    Assignee: Sanofi
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF)
    Publication number: 20190055293
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Application
    Filed: June 28, 2018
    Publication date: February 21, 2019
    Inventors: Catherine R. O'RIORDAN, William H. BRONDYK
  • ANTI-HUMAN CXCR3 ANTIBODIES FOR TREATMENT OF VITILIGO
    Publication number: 20180244787
    Abstract: Provided are methods and uses of anti-CXCR3 antibodies to treat CXCR3-associated disorders such as vitiligo. In certain embodiments, the anti-CXCR3 antibodies are humanized anti-human CXCR3 antibodies with enhanced effector function against cells expressing CXCR3 on their surface.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 30, 2018
    Inventors: William H. Brondyk, Ruiyin Chu, Timothy D. Connors, Sunghae Park, Huawei Qiu, Michele Youd, John Harris, Jillian Richmond
  • Multispecific binding molecules having specificity to dystroglycan and laminin-2
    Publication number: 20180237511
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Application
    Filed: February 16, 2018
    Publication date: August 23, 2018
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • HUMANIZED CXCR3 ANTIBODIES WITH DEPLETING ACTIVITY AND METHODS OF USE THEREOF
    Publication number: 20180214542
    Abstract: Provided are humanized CXCR3 antibodies and methods of using the antibodies to treat CXCR3-associated disorders such as type 1 diabetes mellitus (T1D), particularly new-onset T1D, and psoriasis. In certain embodiments, the anti-CXCR3 antibodies are humanized anti-human CXCR3 antibodies with enhanced effector function against cells expressing CXCR3 on their surface. Also provided are nucleic acid sequences encoding the antibodies, and pharmaceutical compositions comprising the antibodies.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 2, 2018
    Inventors: William H. Brondyk, Ruiyin Chu, Timothy D. Connors, Sunghae Park, Huawei Qiu, Michele Youd
  • Methods to produce rod-derived cone viability factor (RDCVF)
    Patent number: 10035829
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: July 31, 2018
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF)
    Publication number: 20170369541
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Application
    Filed: January 3, 2017
    Publication date: December 28, 2017
    Applicant: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • Methods to produce rod-derived cone viability factor (RdCVF)
    Patent number: 9567382
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: February 14, 2017
    Assignee: Genzyme Corporation
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF)
    Publication number: 20110034546
    Abstract: The invention is related to methods of producing rod-derived cone viability factor (RdCVF). This invention also relates to the treatment of an ocular disease in a mammal using RdCVF. Also provided are expression vectors for high secreted expression of RdCVF of using nucleotide sequences encoding heterologous signal proteins and optionally markers for furin cleavage.
    Type: Application
    Filed: April 15, 2009
    Publication date: February 10, 2011
    Applicant: GENZYME CORPORATION
    Inventors: Catherine R. O'Riordan, William H. Brondyk
  • FSH beta mutants that are glycosilated at residues N55 and T57
    Patent number: 7700112
    Abstract: A novel FSH mutant with increased glycosylation and longer half-lifes for use in inducing folliculogenesis in human patients is described. The FSH mutant permits the use of lower cumulative doses of FSH to achieve the same or better clinical result.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: April 20, 2010
    Assignee: Merck Serono SA
    Inventors: Louise M. Garone, Stephen J. Arkinstall, William H. Brondyk, Robert K. Campbell, Xuliang Jiang, Sean D. McKenna, Mark Tepper
  • Mutant glycoproteins
    Patent number: 7317095
    Abstract: The inventors have designed novel FSH mutants with increased glycosylation and longer half-lives for use in inducing folliculogenesis in human patients. The use of a FSH mutant preparation of the invention permits the use of lower cumulative doses of FSH to achieve the same or better clinical result.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: January 8, 2008
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: William H. Brondyk, Xuliang Jiang, Robert Campbell
  • Methods of increasing endogenous testosterone levels
    Publication number: 20040198799
    Abstract: The present invention relates to the use of substituted pyrazole compounds to increase endogenous testosterone production. Compounds of the invention are useful for the treatment of conditions, disorders or diseases which would benefit patients by increasing endogenous testosterone levels.
    Type: Application
    Filed: March 24, 2004
    Publication date: October 7, 2004
    Inventors: William H. Brondyk, Sean McKenna, Stephen J. Arkinstall